Reuters Health News Summary


Reuters | Updated: 02-02-2019 10:30 IST | Created: 02-02-2019 10:30 IST
Reuters Health News Summary

A U.S. appeals court on Thursday blocked a San Francisco law requiring health warnings on advertisements for soda and other sugary drinks in a win to the American beverage industry which fought the requirements in court. The 11 judges of the 9th U.S. Circuit Court of Appeals in a unanimous decision said the city's ordinance violated commercial speech protected under the U.S. Constitution. A matter of life and death? UK stockpiles drugs as no-deal Brexit feared

With just 56 days until Britain leaves the EU, Jo Elgarf has begun stockpiling food in case politicians fail to strike an exit deal, but she says she cannot do the same with vital drugs her disabled daughter needs. Four-year-old Nora has cerebral palsy and epilepsy and relies on imported Epilim and Keppra daily to stop her suffering seizures. Elgarf wants to stock up on the drugs in case supplies are hit but she can't because they are only available on a monthly prescription. FDA declines to approve Alkermes opioid-based depression drug

The U.S. Food and Drug Administration on Friday declined to approve Alkermes Plc's opioid-based depression treatment, citing the need for additional data to prove the effectiveness of the drug. The largely expected decision comes months after an advisory panel to the FDA strongly voted against the drug and raised questions on its safety and efficacy. Pilgrim's Pride latest company to recall chicken products over rubber contamination

Pilgrim's Pride Corp is recalling about 60,000 pounds of chicken products due to possible rubber contamination, a U.S. public health watchdog said on Friday, making it the third American meat producer in less than a week to recall chicken products. Shares of the Greeley, Colorado-based company fell 1.18 percent to $20.05 following the news on Friday. Teva's migraine drug gets EU panel nod

Teva Pharmaceutical Industries said a European Medicines Agency (EMA) panel on Friday recommended approving migraine treatment Ajovy, a drug that the company has been counting on to revive its fortune. Ajovy was approved by the U.S. Food and Drug Administration (FDA) in September last year and the company had said it was seeing "a very strong launch" of the treatment. Missouri Supreme Court suspends second talc cancer trial in weeks

The Missouri Supreme Court on Thursday halted an upcoming trial in a case brought by women who claim talc supplied by Imerys Talc America for use in Johnson & Johnson products gave them cancer, saying it wanted to consider a jurisdictional challenge by Imerys. It is the second major talc case the Missouri high court has stayed in recent weeks on jurisdictional grounds. Both were in the St. Louis' 22nd Circuit Court, which has issued several large verdicts against J&J and Imerys, including one for $4.7 billion in July. Exclusive: Top U.S. insurer to cover Amgen, Eli Lilly migraine drugs, exclude Teva

A top U.S. pharmacy benefit manager (PBM) owned by UnitedHealth Group Inc has included new migraine drugs from Amgen Inc and Eli Lilly and Co as preferred treatments on its lists of covered drugs, according to an OptumRx client note viewed by Reuters. Teva Pharmaceutical Industries Ltd's rival migraine headache preventer is excluded on one list and patients can pay more for it in some cases on a second list, the note said. Novartis's cancer therapy wins UK backing after initial lymphoma snub

Novartis's Kymriah cell therapy won the blessing of health authorities in England for adult lymphoma patients, the Swiss drugmaker said on Friday, reversing last year's rejection. The list price is 282,000 pounds ($369,000) per patient, given as a single intravenous infusion, but Novartis agreed to offer the therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) at a confidential discounted price, the National Institute for Health and Care Excellence (NICE) said. FDA approves cheaper Botox rival to treat frown lines

An injection to treat forehead wrinkles is set to rival Allergan's Botox after U.S. regulators approved Evolus Inc's cheaper treatment on Friday, sending its shares up about 5 percent after the bell. The approval of Evolus's Jeuveau to treat frown lines comes about eight months after the agency declined to approve the drug, citing deficiencies related to the chemistry and manufacturing of the product.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Give Feedback